Sign in

    Max Moore

    Managing Director and Senior Equity Research Analyst at Citigroup

    Max Moore is a Managing Director and Senior Equity Research Analyst at Citigroup, focusing on the healthcare and biotechnology sectors with detailed coverage of companies such as Vertex Pharmaceuticals, Regeneron, and Gilead Sciences. He has delivered a strong track record with a success rate above 65% on TipRanks and average annualized returns exceeding 12% for his published recommendations. Moore’s career began at JPMorgan in 2008, followed by analyst roles at Goldman Sachs before joining Citi in 2015, where he quickly established himself among the top-rated analysts for healthcare equity research. He is FINRA-registered with Series 7, 63, 86, and 87 licenses, and has been recognized for his accuracy and influence in major Wall Street analyst rankings.

    Max Moore's questions to VERISIGN INC/CA (VRSN) leadership

    Max Moore's questions to VERISIGN INC/CA (VRSN) leadership • Q3 2024

    Question

    Max Moore inquired about Verisign's capital allocation strategy, specifically the future pace of share buybacks and whether the company would consider using leverage to accelerate them. He also requested more specific examples of the new marketing initiatives being rolled out to registrars.

    Answer

    Executive Chairman, President and CEO Jim Bidzos stated that the company maintains a conservative approach to financial stability and increasing leverage is not a priority. EVP and CFO George Kilguss added that Verisign will continue to return excess cash efficiently, consistent with its historical practices. Regarding marketing, Kilguss explained that the new programs offer registrars more choice, with some designed to upsell existing customers and others to attract new ones, all while focusing on higher renewal rate cohorts.

    Ask Fintool Equity Research AI